Pharma NOVA Spółka z Ograniczoną Odpowiedzialnością (KRS 0000359362, NIP 6612347910) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. PHARMA NOVA operates in: Wholesale of pharmaceutical goods (PKD 46.46.Z). Industry: Wholesale trade. The company has been listed in the National Court Register since June 24, 2010. PHARMA NOVA's most recently reported net revenue was 20.5 K PLN for 2024.
Historical suspension of activities
Suspension: July 31, 2018 - resumed: March 1, 2022
Negative equity
Negative equity in 3 of 5 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Pharma NOVA
Identity
- Name
- Pharma NOVA Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 24, 2010
- Registry status as of
- November 21, 2025
- Latest entry
- July 14, 2025
- Founding act
- 25.05.2010 R. - REP. A 5551/2010, NOTARIUSZ PAWEŁ ORŁOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, UL. CHŁODNA 15.
Articles of association history (8)
- May 25, 2010: 25.05.2010 R. - REP. A 5551/2010, NOTARIUSZ PAWEŁ ORŁOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, UL. CHŁODNA 15.
- February 2, 2012: 02.02.2012 R., REP. A 1475/2012, ASESOR NOTARIALNY PAULINA KRAJEWSKA-KUCHARSKA ZASTĘPCA NOTARIUSZA MACIEJA BIWEJNISA, KANCELARIA NOTARIALNA W WARSZAWIE, UL. CHŁODNA 15 - ZMIENIONO § 2 UST. 2; DODANO § 4 UST. 8.
- January 28, 2014: 28.01.2014 R., REP. A 136/2014, NOTARIUSZ MAŁGORZATA TOMCZYK-PERŁOWSKA, KANCELARIA NOTARIALNA W BABICACH NOWYCH, UL. WARSZAWSKA 189 - ZMIENIONO § 2 UST. 6, § 3 UST. 4, § 3 UST. 7, § 4 UST. 6.
- April 27, 2017: 27.04.2017 R., REP. A 1866/2017, NOTARIUSZ GRZEGORZ SIKORA, KANCELARIA NOTARIALNA W PIASECZNIE, UL. PUŁAWIAKÓW 45/48 - ZMIENIONO: § 3 UST. 1, § 3 UST. 4, § 4 UST. 6; WYKREŚLONO § 4 UST. 7; ZMIENIONO OZNACZENIE W § 4 (ZMIANA DOTYCHCZASOWEGO UST. 8 NA UST. 7); ZMIENIONO § 5 UST. 1.
- July 11, 2017: 11.07.2017 R., REP. A 3018/2017, NOTARIUSZ GRZEGORZ SIKORA, KANCELARIA NOTARIALNA W PIASECZNIE, UL. PUŁAWSKA 45 LOKAL 48 - ZMIENIONO § 4 UST. 6.
- December 22, 2017: 22.12.2017 R., REP. A 19107/2017, ZASTĘPCA NOTARIALNY MONIKA HERNIK, ZASTĘPCA NOTARIUSZA PAWŁA ZBIGNIEWA CUPRIAKA, KANCELARIA NOTARIALNA W WARSZAWIE, UL. GRZYBOWSKA 2/26B - ZMIENIONO §2PKT2 I §4PKT 7 23.04.2018 R., REP. A 17417/2018, ZASTĘPCA NOTARIALNY MONIKA HERNIK, ZASTĘPCA NOTARIUSZA PAWŁA ZBIGNIEWA CUPRIAKA, KANCELARIA NOTARIALNA W WARSZAWIE, UL. GRZYBOWSKA 2/26B - ZMIENIONO § 3 UST. 4.
- June 14, 2018: 14.06.2018 R., REP. A NR 3034/2018, EMERYTOWANA NOTARIUSZ BARBARA BRYL, ZASTĘPCA LIDII WOJEWÓDZKIEJ NOTARIUSZ W WARSZAWIE, ZMIANA § 3 UST. 1, § 3 UST. 4
- March 3, 2022: 03.03.2022, NOTARIUSZ MARCIN ŁASKI, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 3664/2022, ZMIANA WSZYSTKICH POSTANOWIEŃ UMOWY SPOŁKI.
Activities
Main activity
46.46.ZWholesale of pharmaceutical goods
Other activities
Address and contact
- Address
- UL. GRZYBOWSKA, 2, 36, 00-131, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - Pharma NOVA
Credibility rating
9.4 / 100
Very poor credibility
Insolvency risk
High
Significant formal threat
Closure risk
56
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
7
7/16 yrs
Board changes
8
8/16 yrs
PKD changes
3
3/16 yrs
Name changes
1
1/16 yrs
Data from 16 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: E (9/100)
Trend: stable (+0.7 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2024
Current: 623.72 PLN
Safe: 87.32 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Pharma NOVA
Founded
June 24, 2010
16 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
46.46.Z
Wholesale of pharmaceutical goods
Share capital
150.0 K PLN
3,000 shares total
Shareholders
4
shareholders
Board
3 people
Filed years
5 years
2018–2024 · profitable: 0/5
Registry entries
37
latest: July 14, 2025
Risk signals
Revenue
20.5 K PLN
2024
Net profit
-692.0 K PLN
2024
Assets
32.8 K PLN
2024
Equity
-1.0 M PLN
2024
EBITDA
-680.6 K PLN
2024
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Pharma NOVA.
No ratings
Related articles
Explainer
Eurocash in 2026: Polish FMCG-wholesale leader and Delikatesy Centrum network, an mWIG40 issuer near Poznań, controlled by Luis Amaral
Eurocash S.A. (KRS 0000213765), headquartered at ul. Wiśniowa 11 in Komorniki near Poznań, is the leader of Poland's FMCG-wholesale distribution and the operator of the 1,500+ Delikatesy Centrum store network. Founded in 1995 by Portuguese entrepreneur Luis Amaral, listed on the WSE since 2005, the company is an mWIG40 constituent. A six-member management board, a five-member supervisory board, chaired by the founder himself.
Explainer
Mercator Medical in 2026: a Kraków-based medical-glove producer with plants in Thailand, an mWIG40 issuer after the COVID meme-stock cycle
Mercator Medical S.A. (KRS 0000036244), headquartered at ul. Modrzejewskiej 30 in Kraków, is a Polish producer and distributor of single-use medical gloves (nitrile and latex) and other disposables. The company controls the full value chain: plants in Thailand (Mercator Medical Thailand) plus Polish and international distribution. In 2020 the share price exploded on pandemic demand (from PLN 10 to over PLN 800), followed by cautious normalisation. Listed on the WSE since 2013. A three-member management board, a five-member supervisory board.
